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Introduction
Systemic juvenile idiopathic arthritis (sJIA) accounts for
10-15% of JIA patients and is characterized by arthritis
with fever, plus rash, generalized lymphadenopathy,
hepatosplenomegaly and serositis. It is associated with
significant morbidity and may be complicated with
macrophagic activation syndrome (MAS). The use of
anti-interleukin 1 (IL1) therapy results in dramatic
improvement in both the systemic and articular disease.
Elevation of liver enzymes can be seen in sJIA patients
because of disease activity, MAS, an infection, hepato-
toxicity from pharmacologic treatment or as manifesta-
tion of another disease (such as autoimmune hepatitis).
Achieving the diagnosis of the hypertransaminasemia in
these patients may be difficult for the clinician.
Objectives
To report 4 patients with sJIA who presented significa-
tive and difficult to interpretate hypertransaminasemia
while being on IL1 blockers.
To identify and review other sJIA patients in our unit
with hypertransaminasemia during anti-IL1 treatment.
Methods
Medical reports from the sJIA patients treated with IL1
blockers in our unit were reviewed.
Results
8 patients out of 30 sJIA patients treated with IL1 block-
ers in our Pediatric Rheumatology Unit since 2004, pre-
sented elevation of liver enzymes during anti-IL1
treatment. In 4 of these 8 patients, hypertransaminasemia
was thought to be related with disease activity or second-
ary MAS. The other 4 cases were more difficult to
interpretate.
Patient 1 presented elevated transaminases (ALT 2254
UI/L) when being 11 months on anakinra (initiated at
disease onset), while prednisone tapering 40 days after a
MAS. ASMA 1/80. IgG elevation. No evidence of dis-
ease flare, MAS, infection, nor other systemic diseases
with liver involvement. Anakinra was stopped and liver
enzymes decreased. Liver biopsy: compatible with auto-
immune hepatitis. Good response to zathioprine.
Anakinra was re-started 4 months later because of a dis-
ease flare without subsequent transaminases elevation.
Patients 2 and 3 presented ALT 1924 UI/L and 852 UI/
L respectively after 3 weeks on anakinra. The workup of
hepatitis did not identify a cause. Anakinra was stopped
with liver enzymes normalization within 2 months.
Patient 4 is a persistent activity patient steroid depen-
dent requiring different drugs during her follow-up. She
presented liver enzymes elevations after one dose of
canakinumab, while being on anakinra, but also after
stopping them; maximum ALT 560 UI/L. Liver biopsy:
inflammatory infiltrate without fibrosis. ASMA 1/80.
IgG elevation. No evidence of infection, nor other dis-
ease with liver involvement. Now she is on anakinra,
azathioprine and prednisone with normal liver tests.
Conclusion
IL1 inhibitors are effective in sJIA.
Hypertransaminasemia in sJIA patients may result a
challenge for the clinician.
The possibility of being related to anti-IL1 treatment
should be taken into account. Three other cases of
hypertransaminasemia in sJIA patients during treatment
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a close monitoring for hepatic toxicity may be indicated
when treating with IL1 blockers.
Autoimmune hepatitis is another diagnostic possibility,
as shown in two of our patients.
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